Lonial, Sagar

An expanded universe of cancer targets

Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 213

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 212

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., et al. (2023) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 209

Association of response endpoints with survival outcomes in multiple myeloma

Lonial, S., & Anderson, K. C. (2014) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 162

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Miller, A., Asmann, Y., Cattaneo, L., Braggio, E., Keats, J., Auclair, D., Lonial, S., The MMRF CoMMpass Network, Russell, S. J., & Stewart, A. K. (2017) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 145

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A., Callander, N., Sborov, D., Suvannasankha, A., et al. (2021) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 144

MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation

Jin, L., Chun, J., Pan, C., Li, D., Lin, R., Alesi, G. N., Wang, X., Kang, H.-B., Song, L., Wang, D., et al. (2018) · Cancer Cell

Melanoma and MAPK PathwaysMetal complexes synthesis and properties

Cited by 132

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D., & Jagannath, S. (2008) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 126

Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma

Gupta, V. A., Matulis, S. M., Conage-Pough, J. E., Nooka, A. K., Kaufman, J. L., Lonial, S., & Boise, L. H. (2017) · Blood

Multiple Myeloma Research and TreatmentsCell death mechanisms and regulation

Cited by 113

Tetrameric acetyl-CoA acetyltransferase 1 is important for tumor growth

Fan, J., Lin, R., Xia, S., Chen, D., Elf, S. E., Liu, S., Pan, Y., Xu, H., Qian, Z., Wang, M., et al. (2016) · Molecular Cell

Cancer, Hypoxia, and MetabolismBiochemical Acid Research Studies

Cited by 106

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Facon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 104

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 95

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Jagannath, S., Heffner, L. T., Ailawadhi, S., Munshi, N. C., Zimmerman, T. M., Rosenblatt, J., Lonial, S., Chanan-Khan, A., Ruehle, M., Rharbaoui, F., et al. (2019) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 85

Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial

Nooka, A. K., Cohen, A. D., Lee, H. C., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E. N., et al. (2023) · Cancer

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 73

Safety of proteasome inhibitors for treatment of multiple myeloma

Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety

Multiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways

Cited by 71

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Scott, S. A., Marin, E. M., Maples, K. T., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2023) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 63

First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Lonial, S., van de Donk, N. W. C. J., Popat, R., Zonder, J. A., Minnema, M. C., Larsen, J., Nguyen, T. V., Chen, M. S., Bensmaine, A., Cota, M., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 49

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

Robinson, M. H., Villa, N. Y., Jaye, D. L., Nooka, A. K., Duffy, A., McCachren, S. S., Manalo, J., Switchenko, J. M., Barnes, S., Potdar, S., et al. (2023) · Journal of Clinical Investigation

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 48

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Kelly, K. R., Ailawadhi, S., Siegel, D. S., Heffner, L. T., Somlo, G., Jagannath, S., Zimmerman, T. M., Munshi, N. C., Madan, S., Chanan-Khan, A., et al. (2021) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 46

Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 46

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Jagannath, S., Chanan-Khan, A., Heffner, L. T., Avigan, D., Zimmerman, T. M., Lonial, S., Lutz, R. J., Engling, A., Uherek, C., Osterroth, F., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 44

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 31

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Lonial, S., Jacobus, S. J., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A., Buadi, F., O'Brien, T. E., Matous, J., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 28